See every side of every news story

Published 14 days ago • loading... • Updated 14 days ago

AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for ...

Summary by Hastings Tribune

EXTON, PA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy, steroid-sparing benefits, and convenient oral administration as central drivers…

1 Articles

1 Articles

Hastings Tribune

AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for ...

EXTON, PA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy, steroid-sparing benefits, and convenient oral administration as central drivers…

14 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated14 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in 14 days ago on Thursday, September 25, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics